Evaluating the relationship between the radial pulse wave and the progression of kidney disease in type 2 diabetic patients

A study on progression diabetic nephropathy by harmonic analysis of pressure pulse waveform

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN14306167

Enrollment

2500

Registered

2018-01-17

Start date

2017-02-08

Completion date

Unknown

Last updated

2024-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Risk factors in diabetes care Nutritional, Metabolic, Endocrine Diabetes

Interventions

All subjects underwent radial pressure wave measurement. Spectrum analysis of radial pressure wave was calculated and transformed into Fourier series coefficients Cn and Pn. The enrolled group is inv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetic patients 2. Aged 30 to 95 years

Exclusion criteria

Exclusion criteria: Severe diseases or acute symptoms are excluded if the pressure wave measurement could not be performed.

Design outcomes

Primary

Measure	Time frame
1. Radial blood pressure wave is assessed using a miniature pressure transducer (TD01C, Taiwan) at time of enrollment 2. Ankle-brachial index is assessed using vascular screening system (VaSera VS-1500N, Japan) at time of enrollment 3. Albumin-to-creatinine ratio level is assessed using urine test at time of enrollment 4. Estimated glomerular filtration rate level is assessed using blood test at time of enrollment 5. Events of composite renal end point: 5.1. Doubling of the serum creatinine level is assessed using blood test 5.2. End-stage renal disease is assessed from the medical record 5.3. Death is assessed from the medical history	—

Measure

Time frame

1. Radial blood pressure wave is assessed using a miniature pressure transducer (TD01C, Taiwan) at time of enrollment 2. Ankle-brachial index is assessed using vascular screening system (VaSera VS-1500N, Japan) at time of enrollment 3. Albumin-to-creatinine ratio level is assessed using urine test at time of enrollment 4. Estimated glomerular filtration rate level is assessed using blood test at time of enrollment 5. Events of composite renal end point: 5.1. Doubling of the serum creatinine level is assessed using blood test 5.2. End-stage renal disease is assessed from the medical record 5.3. Death is assessed from the medical history

—

Secondary

Measure	Time frame
Cardiovascular events and its risk factors, from the medical record at time of enrollment.	—

Countries

Taiwan

Contacts

Public ContactKuo-Meng Liao

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026